Panelists discuss how recognizing the distinct histological patterns and the hallmark loss of INI1 expression in epithelioid sarcoma (ES) can enhance diagnostic precision, inform prognosis, and guide emerging targeted therapeutic strategies.
Summary for Physicians: Histological and Molecular Features of Epithelioid Sarcoma (ES)
Epithelioid sarcoma (ES) typically presents with a painless, slow-growing mass, often in the distal extremities. The classic (distal) subtype is more common in younger patients and generally involves superficial soft tissues, whereas the proximal (large cell) subtype tends to affect older patients and arises in deeper tissues of the pelvis, perineum, or trunk. The proximal subtype is often more aggressive with a worse prognosis.
Histologically, ES is characterized by nodular aggregates of epithelioid and spindle cells with central necrosis, often mimicking granulomatous or epithelial lesions. A key molecular hallmark is the loss of INI1 (SMARCB1) expression, seen in the majority of cases, which aids in diagnosis and may have prognostic and therapeutic implications. The absence of INI1 can help distinguish ES from other morphologically similar tumors and supports the use of targeted therapies currently under investigation. These features play a critical role in accurate diagnosis, prognostication, and guiding treatment decisions.
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.